EDAP TMS Shares Gain More Than 4%; Announces Results Of First Focal HIFU Trial …

EDAP TMS Shares Gain More Than 4%; Announces Results Of First Focal HIFU Trial …

It also offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. In addition, this division leases

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.